Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05106309 | Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants | PHASE1 | COMPLETED | 16 | — | — | Dec 1, 2021 | Feb 1, 2022 | Apr 26, 2022 | - | — |
| Name | Type | Description |
|---|---|---|
| 10 mg CVL-231 as IR formulation | DRUG | Tablets |
| 30 mg CVL-231 as slow-release MR formulation | DRUG | Capsules |
| 30 mg CVL-231 as medium release MR formulation | DRUG | Capsules |
| 30 mg CVL-231 as fast release MR formulation | DRUG | Capsules |
| 30 mg CVL-231 Target Release, Fasted | DRUG | Capsules |
| 30 mg CVL-231 Target Release, Fed | DRUG | Capsules |